Compare M&T Bank Corporation (MTB) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs 10X Genomics Inc — how do they compare? M&T Bank Corporation trades at $237.67 (market cap $34.43B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: M&T Bank Corporation is far larger — about 4× 10X Genomics Inc's market cap, and M&T Bank Corporation pays a 2.52% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| MTB | TXG | |
|---|---|---|
Market Cap | $34.43B | $8.55B |
Sector | Financials | Health |
52-Week High | $254.09 | $67.29 |
52-Week Low | $178.63 | $11.34 |
Dividend Yield | 2.52% | — |
Enterprise Value | — | $8.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTB trades at $238.44, down 0.58% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported three consecutive quarterly EPS beats, with Q2 2026 EPS of $5.35 surpassing the $4.66 estimate. Revenue for 2025 reached $9.63 billion, with a net income margin of 30.85%. Recent news highlights participation in the Barclays Global Financial Services Conference and a declared quarterly dividend of $1.50 per share.
The outlook for MTB is supported by strong earnings performance and a consensus price target of $261.62, implying about 10% upside. However, risks include a negative net cash flow of -$2.01 billion in 2025 and elevated debt levels, with a debt-to-asset ratio of 6.09. Investor sentiment is mixed, with 31% of analysts rating it a buy but 60% recommending hold, reflecting caution amid macroeconomic pressures.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
